資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34350
|
| 標題: | Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region |
| 作者: | Liao, Chia-Te
Yang, Chun-Ting
Toh, Han Siong
Chang, Wei-Ting
Chang, Hung-Yu
Kuo, Fang-Hsiu
Lee, Mei-Chuan
Hua, Yi-Ming
Tang, Hsin-Ju
Strong, Carol
Ou, Huang-Tz |
| 貢獻者: | Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth
Chi Mei Med Ctr, Dept Internal Med, Div Cardiol
Southern Taiwan Univ Sci & Technol, Dept Elect Engn
Natl Cheng Kung Univ, Coll Med, Inst Clin Pharm & Pharmaceut Sci
Chi Mei Med Ctr, Dept Intens Care Med
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
Southern Taiwan Univ Sci & Technol, Dept Biotechnol
Cheng Hsin Gen Hosp, Heart Ctr
Natl Yang Ming Chiao Tung Univ, Fac Med, Sch Med
Chi Mei Med Ctr, Dept Pharm
Chang Gung Univ Sci & Technol, Dept Nursing
Natl Cheng Kung Univ, Coll Med, Dept Pharm |
| 關鍵字: | Heart failure
Dapagliflozin
Cost-effectiveness |
| 日期: | 2021 |
| 上傳時間: | 2023-11-11 11:45:17 (UTC+8) |
| 出版者: | BMC |
| 摘要: | Background: With emerging evidence on the efficacy of adding dapagliflozin to standard care for patients with heart failure with reduced ejection fraction (HFrEF), this study assessed the cost-effectiveness of add-on dapagliflozin to standard care versus standard care alone for HFrEF from the perspective of healthcare systems in the Asia-Pacific region. Methods: A Markov model was applied to project the outcomes of treatment in terms of lifetime medical cost and quality-adjusted life-years. The transition probabilities between health states in the model were obtained from the Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction trial. Country-specific costs and utilities were extracted for modeling. The incremental cost-effectiveness ratio against a country-specific willingness-to-pay threshold was applied to determine the cost-effectiveness of treatment. A series of sensitivity analyses were performed to ensure the robustness of the study results. Costs are presented in 2020 United States dollars. Results: The incremental cost-effectiveness ratios for add-on dapagliflozin versus standard care alone were $5277, $9980, $12,305, $16,705, and $23,227 per quality-adjusted life-year gained in Korea, Australia, Taiwan, Japan, and Singapore, respectively. When using add-on dapagliflozin to standard care versus standard care alone, similar to 100% of simulations were cost-effective at a willingness-to-pay threshold of one gross domestic product per capita of the given Asia-Pacific country; however, the probability of being cost-effective for using add-on dapagliflozin decreased when the time horizon for simulation was restricted to 18 months and when the cardiovascular mortality for the two treatments (43.8% and 33.0%, respectively) was assumed to be the same. The cost-effectiveness results were most sensitive to cardiovascular mortality of treatment. Conclusions: Adding dapagliflozin to standard care is cost-effective for HFrEF in healthcare systems in the Asia-Pacific region, which supports the rational use of dapagliflozin for HFrEF in this region. |
| 關聯: | CARDIOVASC DIABETOL, v.20, n.1, pp.204 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 266 | 檢視/開啟 | | s12933-021-01387-3.pdf | | 1211Kb | Adobe PDF | 77 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
